Medivir/BI deal spotlights RSV pipeline
This article was originally published in Scrip
Executive Summary
Swedish firm Medivir has licensed exclusive global rights to Boehringer Ingelheim's treatment and prevention program in respiratory syncytial virus (RSV) infection. Details of the deal were kept under wraps, but it centers on novel BI compounds that inhibit the RSV fusion protein.